The estimated Net Worth of Leslie D. Funtleyder is at least $3.23 Milion dollars as of 22 August 2024. Mr. Funtleyder owns over 13,530 units of Applied Therapeutics stock worth over $1,447,916 and over the last 6 years he sold APLT stock worth over $1,155,672. In addition, he makes $625,046 as Independent Director at Applied Therapeutics.
Leslie has made over 11 trades of the Applied Therapeutics stock since 2020, according to the Form 4 filled with the SEC. Most recently he sold 13,530 units of APLT stock worth $78,880 on 22 August 2024.
The largest trade he's ever made was exercising 30,000 units of Applied Therapeutics stock on 1 October 2020 worth over $141,000. On average, Leslie trades about 12,038 units every 86 days since 2019. As of 22 August 2024 he still owns at least 277,911 units of Applied Therapeutics stock.
You can see the complete history of Mr. Funtleyder stock trades at the bottom of the page.
Leslie D. Funtleyder serves as Independent Director of the Company. Mr. Funtleyder is a Healthcare Portfolio Manager at E Squared Capital Management. Prior to E Squared Mr. Funtleyder was the Director of Strategic Investments for Opko Health, and held several roles as strategist and portfolio manager for the Miller Tabak Health Care Transformation Fund, Provident Advisors, and UBS Warburg. Mr. Funtleyder wrote Healthcare Investing: Profiting from the New World of Pharma, Biotech, and Health Care Services (McGraw Hill), which bridges the gap between health reform, innovation and investing. He is widely quoted in the Wall Street Journal, the New York Times, and the Financial Times, and is a frequent guest on CNBC, Bloomberg and NPR for his perspective on the healthcare sector and its constituent companies. He is also a consulting partner to Bluecloud Health, a Sub-Saharan healthcare private equity fund, and on the board of several healthcare companies and foundations. He is currently an Adjunct Professor of Public Health at Columbia. Mr. Funtleyder earned his Masters of Public Health from Columbia University Mailman School of Public Health, and studied English and Economics at Tulane University.
As the Independent Director of Applied Therapeutics, the total compensation of Leslie Funtleyder at Applied Therapeutics is $625,046. There are 5 executives at Applied Therapeutics getting paid more, with shoshana Shendelman having the highest compensation of $11,590,000.
Leslie Funtleyder is 50, he's been the Independent Director of Applied Therapeutics since 2016. There are 7 older and 3 younger executives at Applied Therapeutics. The oldest executive at Applied Therapeutics, Inc. is Jay Skyler, 73, who is the Independent Director.
Leslie's mailing address filed with the SEC is C/O APPLIED THERAPEUTICS, INC., 545 FIFTH AVENUE, SUITE 1400, NEW YORK, NY, 10017.
Over the last 6 years, insiders at Applied Therapeutics have traded over $14,309,660 worth of Applied Therapeutics stock and bought 5,072,897 units worth $17,896,654 . The most active insiders traders include Real Estate Equities, Inc.A..., Joel S Marcus oraz Shoshana Shendelman. On average, Applied Therapeutics executives and independent directors trade stock every 26 days with the average trade being worth of $573,736. The most recent stock trade was executed by Leslie D. Funtleyder on 22 August 2024, trading 13,530 units of APLT stock currently worth $78,880.
Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that has completed phase I/II for the treatment of galactosemia in healthy volunteers and adults, as well as is in pediatric clinical study for the treatment of galactosemia in kids; for treating sorbitol dehydrogenase deficiency; and for the treatment of phosphomannomutase enzyme-CDG. The company also develops AT-001 that is in phase III clinical trials for treating diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy. Its preclinical stage products include AT-003 for the treatment diabetic retinopathy; AT-104, a PI3K inhibitor for treating orphan hematological oncology T Cell Acute Lymphoblastic Leukemia. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.
Applied Therapeutics executives and other stock owners filed with the SEC include: